Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Capital Employed (2022 - 2025)

BioXcel Therapeutics has reported Return on Capital Employed over the past 4 years, most recently at 5.56% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 5.56% for Q4 2025, up 871.0% from a year ago — trailing twelve months through Dec 2025 was 5.56% (up 871.0% YoY), and the annual figure for FY2025 was 4.1%, up 609.0%.
  • Return on Capital Employed for Q4 2025 was 5.56% at BioXcel Therapeutics, down from 20.16% in the prior quarter.
  • Over the last five years, Return on Capital Employed for BTAI hit a ceiling of 43.17% in Q2 2025 and a floor of 4.12% in Q1 2025.
  • Median Return on Capital Employed over the past 4 years was 2.35% (2024), compared with a mean of 3.45%.
  • Biggest five-year swings in Return on Capital Employed: crashed -204bps in 2023 and later surged 4552bps in 2025.
  • BioXcel Therapeutics' Return on Capital Employed stood at 0.83% in 2022, then tumbled by -246bps to 2.87% in 2023, then decreased by -9bps to 3.14% in 2024, then soared by 277bps to 5.56% in 2025.
  • The last three reported values for Return on Capital Employed were 5.56% (Q4 2025), 20.16% (Q3 2025), and 43.17% (Q2 2025) per Business Quant data.